Labcorp Holdings Inc. Common Stock (LH)
Stock · NYSE · Health Care
$317.95as of 10/16/2026
Price chart
Active signals
LH Signal Track Record
How signals performed across all stocks →What LH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +1.9% | 53% | September 18, 2026 |
| Bollinger Band Breakout | 29 | +2.8% | 55% | August 21, 2026 |
| 200-Day Moving Average TouchActive now | 28 | +1.6% | 57% | June 24, 2026 |
| Bollinger Band Breakdown | 24 | +1.9% | 54% | September 10, 2026 |
| Any 20-session window (baseline) | +0.8% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LH
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse te…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 71,000
- Website
- www.labcorp.com/
Fundamentals
- 1-day range
- $314.28$319.75
- Market cap
- $25.96B
- P/E (trailing)
- 25.55
- P/E (forward)
- 16.11
- EPS (trailing)
- $12.09
- Dividend yield
- 1.35%
- Beta
- 0.89
- Avg. volume
- 740.8K
- Ex-dividend date
- August 28, 2026
- Dividend pay date
- September 11, 2026
How Labcorp Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
16 analyst ratings
Labcorp Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LHLabcorp Holdings Inc. Common Stock$317.95▼ 2.19%Market cap $25.96BP/E 25.55$244.52$341.8
- DGXQuest Diagnostics Incorporated Common Stock$235▼ 1.74%Market cap $26.32BP/E 24.67$171.18$248.84
- ILMNIllumina Inc. Common Stock$262.54▼ 2.01%Market cap $29.25BP/E 48.62$88$309.35
- GHGuardant Health Inc. Common Stock$158.6▼ 4.39%Market cap $21.15BP/E —$61$191.05
- CNCCentene Corporation Common Stock$69.16▼ 1.91%Market cap $31.71BP/E —$31.63$70.37
- NTRANatera Inc. Common Stock$393.44▼ 2.80%Market cap $38.01BP/E —$170.82$437.41
- MOHMolina Healthcare Inc Common Stock$207.36▼ 2.42%Market cap $10.02BP/E 1257.31$121.06$244.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LH Labcorp Holdings Inc. Common Stock | $25.96B | 25.55 | $317.95 | ▼ 2.19% | $244.52$341.8 |
| DGX Quest Diagnostics Incorporated Common Stock | $26.32B | 24.67 | $235 | ▼ 1.74% | $171.18$248.84 |
| ILMN Illumina Inc. Common Stock | $29.25B | 48.62 | $262.54 | ▼ 2.01% | $88$309.35 |
| GH Guardant Health Inc. Common Stock | $21.15B | — | $158.6 | ▼ 4.39% | $61$191.05 |
| CNC Centene Corporation Common Stock | $31.71B | — | $69.16 | ▼ 1.91% | $31.63$70.37 |
| NTRA Natera Inc. Common Stock | $38.01B | — | $393.44 | ▼ 2.80% | $170.82$437.41 |
| MOH Molina Healthcare Inc Common Stock | $10.02B | 1257.31 | $207.36 | ▼ 2.42% | $121.06$244.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?Yahoo · 9/30/2026
- Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026Yahoo · 9/30/2026
- Is This the Right Time to Add Labcorp Stock to Your Portfolio?Yahoo · 9/29/2026
- 3 Low-Volatility Stocks That Concern UsYahoo · 9/29/2026
- Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong BuySeekingAlpha · 9/23/2026
- Labcorp Holdings (LH) Eyes Acquisitions And Lab Tech Investment After 2026 Investor DayYahoo · 9/23/2026
- 2 Small-Cap Stocks to Research Further and 1 Facing ChallengesYahoo · 9/23/2026
- Is Labcorp Holdings Stock Outperforming the Dow?Yahoo · 9/23/2026
Insider Activity
Insider Actions →- Bryan T. Vaughn · September 1, 2026 · Grant1.5K
- Jonathan C. Meltzer · September 1, 2026 · Grant900
- Akinbolade Oyegunwa · September 1, 2026 · Grant750
- Brian J. Caveney · September 1, 2026 · Grant3.0K
- Kerrii B. Anderson · August 17, 2026 · Sale3.0K @ $318.02
- Adam H. Schechter · August 11, 2026 · Sale4.7K @ $320.37
- Amy B. Summy · August 4, 2026 · Sale924 @ $306.74
- Peter J. Wilkinson · August 3, 2026 · Sale82 @ $309.22
- Peter J. Wilkinson · August 3, 2026 · Option Exercise1.3K @ $209.25
- Peter J. Wilkinson · August 3, 2026 · Sale1.3K @ $309.23
- Bryan T. Vaughn · July 2, 2026 · Sale234 @ $286.19
- Kathryn W. Kyle · July 2, 2026 · Sale92 @ $286.19
- Bryan T. Vaughn · July 1, 2026 · Option Exercise327
- Bryan T. Vaughn · July 1, 2026 · Tax Withholding93 @ $283.88
- Kathryn W. Kyle · July 1, 2026 · Option Exercise256
Institutional Ownership
March 31, 2026
- Total shares held
- 71.93M
- Total value held
- $18.19B
- Institutional holders
- 1007
- Unknown6.44M
- Unknown5.38M
- Unknown4.63M
- Unknown3.86M
- Unknown2.37M
- Unknown2.23M
- Unknown2.19M
- Unknown2.17M
- Unknown1.50M
- Unknown1.33M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.